Missouri Officials Update Cannabis Industry Rules to Address Middlemen Concerns

a word from our sponsors:

advertisement

advertise here

New cannabis industry regulations proposed by the Missouri Department of Health and Senior Service’s Division of Cannabis Enforcement would require the registered designated contact for all the state’s cannabis microbusiness licenses to be the owner or partial owner of the company, the Missouri Independent reports.

Under the state rules, each microbusiness operator assigns a person to be their designated contact with the state. The proposed rulechange aims to prevent “predatory” middleman business practices, according to the agency, where a person registered as the designated contact for a cannabis licensee can intercept official communications, keeping the operator in the dark about some business and licensing dealings.

“These revisions are intended to ensure microbusiness licenses are issued to eligible individuals… and to address the trend of predatory arrangements in microbusiness licensing. Specifically, these draft rule revisions should mitigate the ongoing efforts of ineligible entities to acquire licenses by taking advantage of eligible individuals.” — Division of Cannabis Enforcement statement, in a press release

The designated contact role was originally designed to improve communication between industry operators and officials.

Notably, many individuals are currently registered as the designated contact for multiple cannabis entities, including one Missouri consultant who appeared on 329 social equity license applications last year and a Michigan-based attorney who was listed on another 94, the report said. Of the designated contacts registered with the state, 68 have appeared on multiple applications, accounting for nearly three-quarters (74%) of the total applications received in April.

 

End


Virginia Cannabis Sales Bill Passes Senate Committee

a word from our sponsors:

advertisement

advertise here

A bill to create a legal framework for adult-use retail cannabis sales in Virginia passed through the Senate Rehabilitation and Social Services committee last week, Cardinal News reports. The proposal was referred to the House Finance and Appropriations Committee. 

The measure would allow the state Cannabis Control Authority (CCA) to begin issuing adult-use cannabis licenses on September 1, but would not permit legal sales to commence until May 1, 2026.  

Sen. Aaron Rouse (D) Virginia Beach, during a presentation of the bill, told the Senate panel that the legislation “prioritizes public safety in creating a well-regulated marketplace that keeps adult products out of the hands of kids.”  

“The safety and security of all Virginians is a top priority of this legislative body and in recent years we have seen an unchecked proliferation of illegal and unregulated marijuana stores. This has put Virginians at risk.” — Rouse via Cardinal News 

Virginia lawmakers passed adult-use reforms in 2021, during the administration of Democratic Gov. Ralph Northam; however Republican Glenn Youngkin was elected in 2022 and has vowed to not allow legal sales to progress during his time in office. Republicans in the House of Delegates have also pushed back on allowing legal sales, blocking legislation to create a retail licensing framework in 2022 and 2023. 

Youngkin vetoed a similar bill last year and the Senate sustained the action.  

End


Toronto Officials to Stop Crackdowns on Illegal Cannabis Shops in the City

a word from our sponsors:

advertisement

advertise here

Officials in Toronto, Ontario, Canada will stop cracking down on illegal cannabis shops in the city due to budgetary and safety concerns, CBC reports. During a council budget committee last week, Carleton Grant, the city’s executive director of municipal licensing and standards, said shutting down the shops should be the responsibility of law enforcement. 

“We’ve made efforts over the last five to six years to close them down, to put up concrete blocks that are only to be removed within 24 hours. We have boarded up buildings. We have been countersued for locking a tenant into a business. We have used every tool available to us.” — Grant via CBC  

The city received C$8.97 million in 2018 from the Ontario Cannabis Legalization Implementation Fund to help municipalities with local costs associated with adult-use cannabis legalization, including enforcement, but the funding ran out by the end of 2024, Grant said.  

Grant added that the municipal bylaw enforcement officers who investigated and shut down the shops “do not have arrest powers and are not permitted or trained to use force while carrying out enforcement activities,” which “makes the enforcement of unlicensed cannabis dispensaries challenging and presents health and safety risks to officers.” 

Keesha Seaton, spokesperson for the Ontario Ministry of the Attorney General, told CBC that the province “will continue to ensure there is integrity in the regulated market by working with all partners” but did not specify who the agency would work with in Toronto. Last year, the provincial government announced it would provide C$31 million over three years to support cannabis enforcement efforts. The funds will enable the Provincial Joint Forces Cannabis Enforcement Team to respond to illegal cannabis production, sale, and distribution.

End


Two Cannabis Industry Associations Merge to Create ‘Singular’ Industry Voice

a word from our sponsors:

advertisement

advertise here

The two largest cannabis industry groups in the U.S. – the National Cannabis Roundtable (NCR) and US Cannabis Council (USCC) – last week announced they are combining the organizations to form the United States Cannabis Roundtable (USCR). The group said the combination will establish “a singular voice” representing in the industry to the 119th Congress and the administration of President Donald Trump (R). 

In a statement, Charlie Bachtell, CEO of Cresco Labs and chairperson of both NCR and USCC, called the newly elected Congress and the new presidential administration “a pivotal time for the regulated cannabis industry” noting that Trump “has publicly supported and pledged to advance commonsense cannabis reform.”    

“As the chairman of both groups, I have seen first-hand the incredible talent of each organization and know that the combined group will be the unified authority advocating on behalf of the legal cannabis industry and a resource on all things cannabis for members of the Trump Administration and Congress.” — Bachtell in a press release 

During the campaign Trump endorsed a states’ rights legislative approach to cannabis, reclassifying cannabis from Schedule I to Schedule III under the federal Controlled Substances Act (CSA), and the SAFE Banking Act, which the USCR described as priorities. 

Former President Joe Biden (D) had directed the Justice Department to reschedule cannabis from Schedule I to Schedule III; however, the policy reforms were not finalized before the end of his term. A recent court hearing on the matter was canceled by Drug Enforcement Administration (DEA) Administrative Law Judge John Mulrooney due to a legal challenge from advocacy groups Hemp for Victory and Village Farms International, Inc. who claimed the DEA’s opposition to rescheduling cannabis under the CSA makes the agency unfit to lead the rescheduling hearing and asked the judge to remove the DEA from the proceedings.   

Kim Rivers, CEO of Trulieve and vice chair of NCR, said Trump’s “endorsement represents a sea change in cannabis policy and advocacy.” 

“For the first time in history, a Republican president endorsed these initiatives,” Rivers said in a statement, “and our new combined organization will best position the industry to help the President get them over the finish line.”  

The USCR will combine the political activities, lobbying efforts, and public-facing communications of the NCR and USCC and represent operators across 38 states and a substantial number of the 13,000 retail locations and nearly 450,000 full-time employees working in state-licensed cannabis industries.

End


Indiana Proposal Would Legalize Adult-Use Cannabis

a word from our sponsors:

advertisement

advertise here

Several Republican lawmakers in the Indiana House of Representatives have introduced a proposal to legalize adult-use cannabis, FOX 59 reports.

Authored by state Rep. Heath VanNatter (R), the proposal would legalize cannabis possession and consumption by adults aged 21+ and establish a taxed-and-regulated system for the production and retail of cannabis. The program would include a 10% excise tax on cannabis sales

”It’s time for Indiana to join our neighbors and most of the rest of the country in legalizing marijuana,” VanNatter said.

“This unique approach of moving directly to a regulated, adult-use market allows us to engage law enforcement early in the policy-making process to address issues comprehensibly, pragmatically, rather than piecemeal.” — VanNatter, in a statement

The proposal’s future is unclear as its survival in the House is far from guaranteed, and it may face an even tougher battle in the Senate where lawmakers like state Sen. Liz Brown (R) are more favorable to decriminalization language, suggesting that adult-use legalization would be a step too far, the report said.

If approved, however, Indiana would be the first state to jump from cannabis prohibition straight to an adult-use program (there are currently no exceptions for medical use under state law).

Meanwhile, a poll published last November found that a 70% supermajority of Indiana voters support adult-use cannabis legalization. Additionally, Indiana’s neighboring states of Illinois, Michigan, and Ohio have adult-use cannabis programs in effect, while Kentucky has legalized medical cannabis.

End


Florida Advocates Launch 2026 Cannabis Legalization Campaign

a word from our sponsors:

advertisement

advertise here

Advocates with the Smart & Safe Florida campaign have launched a new cannabis legalization initiative that aims to appear before voters in 2026, CBS reports. The new campaign comes just a few months after the Amendment 3 legalization campaign failed last November with only about 57% voter support (constitutional amendments in Florida require a 60% supermajority of voter support to pass).

The new ballot initiative is a revamped version of last year’s proposal but advocates have taken steps to address some of the concerns highlighted by critics of Amendment 3, including new language that specifies “smoking and vaping of marijuana in any public place is prohibited” and new rules against cannabis advertising and packaging that could be considered “attractive to children.” Additionally, like the previous proposal, the new initiative would allow the state’s current medical cannabis operators to begin servicing Florida’s adult-use market. However, the initiative would also require lawmakers to “adopt legislation for the licensure and regulation” of other adult-use operators, the report said.

The new initiative would also exempt new operators from state rules requiring the cannabis industry to be vertically integrated, which would enable wholesale operations and other specialist roles for the industry.

Last year’s cannabis reforms effort in Florida was the most expensive legalization campaign ever — advocates raised over $152 million, more than 94% of which was contributed by Trulieve, the state’s largest medical cannabis operator.

End


New York Supreme Court Judge Rules Warrantless Raids on Unlicensed Cannabis Sellers Illegal

a word from our sponsors:

advertisement

advertise here

A New York Supreme Court Judge on Monday ruled that warrantless raids on unlicensed cannabis shops by the New York City Sheriff’s Office and Office of Cannabis Management (OCM) must cease and that violation notices affixed to the shops by OCM and law enforcement must be removed.

Plaintiffs in the case include Super Smoke n Save LLC, in Saratoga Springs; Two Strains Cannabis Co. LLC, in Queensbury; Brecken Gold Athletics NYC LLC, in Manhattan; and Breckenridge Café NYC LLC, and 7 Leaf Clover, both in Brooklyn.

In the Decision and Order, Justice Thomas Marcelle said the agency and law enforcement officials carrying out the raids acted outside their authority and that inspections of businesses suspected of selling cannabis without a license can be conducted by “only OCM.” Marcelle noted that “OCM inspectors are trained on the statutory, scientific, and administrative distinction between hemp and marijuana” while “sheriff deputies are not.”

“In sum, how respondents conducted their enforcement activities against petitioners was a far cry from an administrative inspective seeking to cull evidence of regulatory violations. The court often hears cases, like those from agriculture and markets, involving state inspectors inspecting businesses – there, regulators come armed with clipboards, forms and pens, and not guns, bulletproof vests and handcuffs.” — Marcelle in the Decision and Order, 1/13/25

Marcelle also wrote that the decision by the Sheriff’s Office to destroy product upon seizing was shocking, noting that OCM never performed testing to confirm the products were unlawful cannabis products and not hemp-derived, and therefore legal under state and federal law.

“This willful ignorance as to the nature of the products exposes a search that is not administrative in nature,” Marcelle wrote.

The judge ruled the sheriff’s raids violated the businesses’ Fourth Amendment Rights.

“The Supreme Court has told governments that seek to conduct warrantless searches that they must place statutory limits on the administrative agents who seek out contraband without a warrant – this has not been done,” Marcelle wrote in the order. “The court, therefore, believes it highly probable that petitioners will succeed on the merits of their claim that OCM violated their rights secured by the Fourth Amendment.”

End


Arkansas Gov. Plans to Use Medical Cannabis Tax Revenues to Fund Free School Meals

a word from our sponsors:

advertisement

advertise here

During her State of the State address on Tuesday, Arkansas Gov. Sarah Huckabee Sanders (R) said she plans to use tax revenues from medical cannabis to provide free meals in schools throughout the state.   

“I’ve already announced that Arkansas will participate in summer EBT this year. And today, I’m announcing my plan to use medical marijuana money to make both this program and our free lunch and breakfast programs financially sustainable for years to come.” — Huckabee Sanders during State of the State, 1/14/25 

According to state Department of Finance and Administration (DFA) data, medical cannabis sales in Arkansas totaled $250 million through November 2024 and the two state taxes on medical cannabis sales generated $28.5 million in 2024, DFA spokesperson Scott Hardin told KATV.   

Sanders suggested also using medical cannabis tax revenues for the summer EBT program in an effort to end the state grocery tax, which she referred to as the state’s “most regressive.” 

There are over 109,000 medical cannabis patient cards issued in Arkansas. Voters approved the medical cannabis law in November 2016. Medical cannabis sales carry a 6.5% sales tax which is currently used for public school funding and efforts to combat food insecurity in the state. 

End


Workers at Four Nevada Cannabis Businesses Ratify First Union Contract

a word from our sponsors:

advertisement

advertise here

Workers at three Ayr Wellness dispensaries and a delivery depot in Nevada last week ratified their first union contract. The dispensary and delivery workers are unionized with the United Food and Commercial Workers (UFCW) Local 711. 

Included in the contract are the implementation of armed security at dispensaries, improved access to affordable health care, and better scheduling opportunities.   

In a statement, Chase Payne, an Ayr Wellness budtender from the Las Vegas Eastern Ave. Location, said the “contract represents more than just words on paper; it’s a testament to our resilience, unity, and unwavering commitment to the cannabis industry.” 

“We fought for fair wages, safe conditions, and respect – not just for ourselves, but for everyone who will come after us. This victory proves that when we stand together, we are unstoppable.” — Payne in a press release 

Steve Shehata, an Ayr Wellness budtender from the Las Vegas Decatur Blvd. Location, added that the workers are “laying the foundation for more growth and opportunity within our industry and ensuring that we have livable wages, affordable health care, and an all around sound quality of life.” 

UFCW has emerged as the largest cannabis industry union in the U.S. According to its website, it has amassed 418 organizing wins since 2020 with 290 dispensaries and 36 cultivation facilities organized with the union.     

End


Former High Times Chairman to Plead Guilty to Fraud Scheme

a word from our sponsors:

advertisement

advertise here

Adam Levin, founder and chairman of Hightimes Holding Corp.—the parent company of High Times magazine—has agreed to plead guilty to conspiracy charges involving undisclosed payments to a stock analyst. According to the U.S. Department of Justice, Levin participated in a scheme to pay over $150,000 to an investment newsletter analyst who promoted Hightimes’ stock without disclosing the compensation.

The plea agreement, filed on December 20, 2024, outlines that these undisclosed payments were intended to boost investor interest in Hightimes’ securities offering. The analyst’s promotions, lacking transparency about the financial arrangement, contributed to Hightimes raising at least $6 million from investors.

Levin is scheduled to appear in United States District Court in Los Angeles on January 17, 2025, to formally enter his guilty plea. The charge of conspiracy to tout securities for undisclosed compensation carries a statutory maximum sentence of five years in federal prison.

Levin’s guilty plea adds to a series of challenges faced by Hightimes Holding Corp. in recent years, including accusations of fraud, CEO resignations, and an eventual collapse of the business — culminating last year, when the company entered receivership after failing to meet its financial obligations.

Hightimes Holding Corp. acquired High Times magazine in 2017. The acquisition was part of a $70 million deal by a group of investors led by Adam Levin, the founder of Oreva Capital. The purchase included the magazine, its intellectual property, and its events business, such as the Cannabis Cup. According to public statements at the time, the acquisition aimed to transform High Times into a broader media, lifestyle, and events company while capitalizing on the growing cannabis industry’s potential.

In 2018, Hightimes Holding Corp. initiated a Regulation A (Reg A) public offering, allowing non-institutional investors to purchase shares directly. This fundraising strategy aimed to generate up to $50 million to support the company’s expansion plans, including acquisitions and a potential public listing. However, by June 2019, the company had raised only $15 million, falling short of its goal. Additionally, in July 2020, the U.S. Securities and Exchange Commission ordered a halt to the High Times IPO after the company missed its annual report deadline.

During this period, Hightimes Holding Corp. aggressively pursued several acquisitions. In September 2018, the company acquired a handful of cannabis industry publications, including Seattle-based cannabis journal DOPE Magazine (not to be confused with the art publication by the same name), aiming to expand its reach within the cannabis culture and lifestyle sector. However, by October 2019, High Times laid off the majority of DOPE Magazine’s editorial team in Seattle and consolidated operations to its Los Angeles headquarters until the publication stopped posting altogether in 2021.

Hightimes Holding Corp. has not issued a public statement regarding Levin’s plea agreement at this time. The investigation was conducted by the Federal Bureau of Investigation and the U.S. Securities and Exchange Commission. For more information, refer to the official press release from the U.S. Department of Justice.

End


Judge Cancels Cannabis Rescheduling Hearing Amidst Legal Challenges

a word from our sponsors:

advertisement

advertise here

The hearing for expert testimony on moving cannabis from Schedule I to Schedule III under federal law was canceled this week by DEA Administrative Law Judge John Mulrooney, who was set to oversee the hearing, on account of a recent legal challenge, Marijuana Moment reports.

The challenge — filed earlier this month by the advocacy group Hemp for Victory and Village Farms International, Inc. — claimed the DEA’s opposition to rescheduling cannabis under the federal Controlled Substances Act (CSA) makes the agency unfit to lead the rescheduling hearing and asks the judge to remove the DEA from the proceedings. The groups also described inappropriate communications between anti-rescheduling proponents and DEA officials, which Mulrooney called a “disturbing and embarrassing revelation.”

The judge, however, said the communications don’t disqualify the agency from its role in the hearing as the main “proponent” for rescheduling — a fact that the actual rescheduling proponents also highlighted as concerning — but he granted the groups’ request for leave to file an interlocutory appeal, the report said.

The hearing, which was scheduled to take place on January 21, will be delayed at least another three months. It’s also possible the hearing could be canceled indefinitely as the incoming administration’s priorities are unclear in regard to federal cannabis policy.

President Biden first initiated the review process for rescheduling cannabis in 2022.

End


Portland Dispensary Facing Lawsuit After Customer Experiences ‘THC Overdose’

a word from our sponsors:

advertisement

advertise here

A man is suing the Portland, Oregon cannabis dispensary Arcanna for $10,000 after he says he was recommended an excessively potent cannabis product that landed him in the emergency room, The Oregonian reports.

The plaintiff in the suit Skye Fitzgerald claims that an employee of the shop, despite being informed that Fitzgerald was a novice consumer, recommended that he purchase an excessively potent THC syrup. When Fitzgerald got home, per the employee’s advice, he followed the directions on the bottle and consumed about a teaspoon of the syrup, or about 40 milligrams of THC, according to the suit.

He ultimately went to the emergency room for symptoms including “muscle spasms, psychomotor agitation, elevated heart rate, extreme discomfort, shortness of breath, nausea, vomiting, hypokalemia, and muscular paresis,” and the doctors there “diagnosed him with THC overdose,” the lawsuit says.

The shop’s managing director Kris Snider said in the report that because the product purchased by Fitzgerald had been approved by the OLCC, Arcanna couldn’t be held at fault for Fitzgerald’s bad experience. Additionally, he said budtenders have no way of knowing customers’ tolerance levels and that the budtender who serviced Fitzgerald had recommended only taking “a few drops” of the syrup.

“At the end of the day, it’s like going to a bar and asking the bartender ‘How much alcohol is going to get me drunk?’ You don’t hear of anybody suing the bar because somebody got drunk.” — Snider, via The Oregonian

Notably, Oregon state law requires cannabis edibles to carry a maximum serving size of 10 mg but the rules don’t explicitly address serving size limits for cannabis tinctures, concentrates, or extracts, which the syrup product could have fallen under.

End


Unique Preroll Trends

Trends in Cannabis and Hemp Prerolls: Premium Options and Custom Formulas

a word from our sponsors:

advertisement

advertise here

The preroll market has grown rapidly as consumers are constantly looking for fresh and new ways to experience smokeable cannabis and hemp products without sacrificing quality and convenience. Evolving preferences are reshaping the market—from infused varieties to customizable prerolls—delivering premium quality smokables with unique formulas that excite consumers.

Whether you’re a retailer, wholesaler, or a brand looking to expand their product line, these unique designs provide a diverse set of in-demand options to an ever-growing market.

Premium Prerolls: Elevating the Experience

Prerolls remain one of the most dominant smokable product categories on the market. While many consumers still prefer the classic preroll experience, others are eager to explore more exotic options. Today’s premium prerolls combine flavor, potency, and appearance to create a sensory experience that captivates consumers.

Infused and coated prerolls, such as Moonrock, Diamond, and Snow prerolls, are growing in popularity due to their potency, unique smoking experience, and visual appeal. These premium prerolls cater to a wide range of preferences, from seasoned smokers to new hemp tokers.

A Range of Styles and Potencies

In a saturated market, companies must find ways to stand out while meeting the ever-changing demands of consumers. Visually striking and potent preroll options have emerged as leaders in this trend, offering something for every type of customer. Here are some of the top preroll designs shaping the playing field:

  • Standard Prerolls – Simple and classic, these prerolls are perfect for consumers who appreciate a straightforward, smooth experience.
  • Moonrock Prerolls – Known for their kief coating, these prerolls are a favorite among those looking for an enhanced, flavorful smoke.
  • Diamond Prerolls – Featuring a diamond-coated tip, these prerolls deliver a premium experience and make an eye-catching addition to any retailer’s lineup.
  • Snow Prerolls – Coated with hemp-derived diamonds, these prerolls offer both potent effects and stunning visual appeal.
  • Diamond Moonrock Prerolls – A combination of kief coating and a diamond tip, this preroll merges two premium features into one unforgettable product.

Types of Prerolls

Customization: Unlocking New Opportunities

Customization is reshaping the preroll market, empowering brands to develop products that truly stand out. This trend goes beyond aesthetic tweaks—it’s about creating tailored experiences that meet specific customer needs and preferences. Here are key aspects of preroll customization that companies can leverage:

  • Unique Cannabinoid Blends: Adjusting the ratios of cannabinoids to target specific effects or consumer preferences, whether it’s relaxation, focus, or creativity.
  • Terpene Customization: Infusing unique terpene profiles to enhance flavor and aroma, adding another layer of sophistication to prerolls.
  • Exclusive Visual Features: Utilizing techniques like kief coating, diamond tips, or other design elements to make prerolls instantly recognizable.
  • Private Label Opportunities: Offering white-label packaging solutions so brands can seamlessly integrate prerolls into their product line with their own branding.

By leveraging these customization options, brands can differentiate themselves in a competitive market, building loyalty and attracting a broader range of customers.

Scaling Production and Navigating Compliance in the Preroll Market

Scaling production while maintaining quality is a significant challenge, particularly in labor-intensive processes like preroll production. Intricate steps such as blending custom cannabinoid profiles, applying kief coatings, or crafting diamond tips require precision and time. Emerging technologies—automated rolling machines, precision coating applicators, and terpene infusion systems—are helping bridge the gap between high demand and labor limitations. These innovations streamline production, reduce manual labor, and ensure consistent, artisanal-quality products at scale, keeping brands competitive in an evolving market.

While technological advancements drive efficiency, the cannabis and hemp industries face complex regulatory hurdles, especially for prerolls incorporating extracts, concentrates, and flower. Each step, from extraction to infusion and final assembly, involves layered oversight and licensing requirements. Successfully navigating these challenges demands expertise in compliance and quality assurance. Experienced producers streamline operations by ensuring all regulatory steps are met, enabling brands to focus on innovation without risking non-compliance.

By combining scalable production methods with meticulous regulatory adherence, businesses can meet growing consumer demand for premium preroll products. Collaboration with trusted manufacturing partners ensures quality and compliance while embracing technologies that improve efficiency. As the market evolves, innovation and adaptability will remain key to delivering high-quality, customizable prerolls that resonate with both seasoned and new consumers alike.

Closing Thoughts

As the cannabis and hemp preroll markets continue to evolve, staying ahead of trends and navigating industry challenges requires adaptability and innovation. By embracing advancements in production, customization, and compliance, businesses can meet the growing demand for premium preroll products. The future of this market lies in collaboration, ensuring high-quality products that resonate with consumers and adapt to changing regulations.

End


Ohio Cannabis Sales Total $242M in 2024

a word from our sponsors:

advertisement

advertise here

Cannabis sales in Ohio totaled $242 million in 2024, according to state Division of Cannabis Control (DCC) data. Adult-use sales in the state commenced in August and in the five months since the program launched, cannabis operators sold more than 32,000 pounds of raw plant material, and 4 million pounds of manufactured products have been sold in dispensaries throughout the state.

Medical cannabis sales topped $2.05 billion which outpaced last year’s sales of about $1.6 billion. 

From the launch of adult-use sales, the price-per-gram of cannabis flower in Ohio fell from $9.40 to $6.74, while the average sale price for manufactured products fell from $31.06 to $26.76. 

State regulators are seeking changes to the state’s cannabis industry in 2025 with the DCC considering allowing retailers to sell pre-roll products, including so-called “super pre-rolls” or infused pre-roll products, but also implementing a ban on cannabis advertising via methods “with a high likelihood of reaching persons under the age of 18” which would effectively bar cannabis companies from advertising on billboards, radio, television, and online. The DCC is also considering discount rules that specify that each dispensary must have a written discount policy and that any discount offered to adult-use customers must be available to medical cannabis patients, and that dispensary employees cannot receive any rebates or discounts.

End


Customer Data of Cannabis Brand Stiiizy Exposed in Data Breach

a word from our sponsors:

advertisement

advertise here

Cannabis brand Stiiizy has been victimized by a third-party data breach that exposed customer identification information and transaction history, Cybernews reports. Stiiizy said that multiple California retailers were impacted, including four dispensaries – one in Alameda, one in Modesto, and two San Francisco. 

According to Cybernews’ ‘Ransomlooker’ tool, the brand was compromised by ransomware Everest in November and December of last year. 

In a Notice of Data Breach filed with the California Office of the Attorney General on January 8, Stiiizy said they were notified of the first attack on November 20, 2024.  

“STIIIZY has implemented additional security measures designed to prevent a recurrence of such an attack and to protect the privacy of STIIIZY’s valued customers, Additionally, we are providing affected individuals with free credit monitoring services, as described more fully below.” — Stiiizy in the Notice of Data Breach, 1/8/25 

The impacted information includes customer names, addresses, birth dates, driver’s license and passport ID numbers, photographs, signatures that appear on government-issued IDs, medical cannabis card information, and transaction histories. According to cybersecurity firm Halcyon AI, the personal information of more than 420,000 Stiiizy customers was breached in the ransomware attack. 

Given that the leaked information includes sensitive data like government ID numbers and individual signatures linked to the IDs, hackers could impersonate the victims or commit financial fraud. Bad actors could also use the information to extort victims or create personalized and targeted scams against Stiiizy customers.

End


New York Cannabis Retailers Say Officials Are Ignoring Industry Spacing Rules

a word from our sponsors:

advertisement

advertise here

A group of New York cannabis dispensary owners filed a lawsuit against state regulators last week claiming they allowed dispensaries to open too close to one another, violating the state’s rules prohibiting dispensaries from opening within 1,000 feet of one another. Four dispensary owners in Manhattan and Brooklyn allege that the Office of Cannabis Management (OCM) allowed shops to violate the 1,000-foot rule, running afoul of regulations that would only allow shops to open within 1,000 feet of another shop if there is a “demonstrated need.” 

Actualize Dispensary, Astro Management, L.O.R.D.S, and R&R Remedies, the plaintiffs in the lawsuit, contend that OCM did not properly conduct a required review before granting the waivers for the shops to open within 1,000 feet of their already existing dispensary.  

In a statement, Jillian Dragutsky, CEO of Astro Management, said the Cannabis Control Board (CCB) recently granted a Public Convenience Waiver to a dispensary seeking to open within 1,000 feet from a dispensary owned by Astro Management, which puts the company “in an untenable position” and “endangering its viability as a business” when the dispensary is “only weeks away from launching.” 

“It’s as though the rug were pulled from under us without notice or reason. It seems clear to me that the CCB has chosen arbitrarily to ignore the statutory requirements it is legally bound to follow when considering whether to approve an application for a Public Convenience Waiver for a particular location. This must stop; the Cannabis laws, its rules and regulations issued by the state of New York which the OCM and CCB are charged with following and enforcing, must be followed without any latitude.” — Dragutsky in a press release  

Osbert Orduña, CEO of The Cannabis Place dispensary and co-chair of the Service Disabled Veterans in Cannabis Association and the National Hispanic Cannabis Council’s Tri-State Chapter, said the “CCB continues to act with capriciousness and in violation of its own proximity regulations.” 

“By arbitrarily issuing waivers, these governmental organizations are undermining the very communities they claim to be supporting,” Orduña said in a statement. “We are asking for the CCB and OCM to be true to their originally stated intention to provide opportunities for various classes of licensees.” 

Vaughn Jefferson, majority owner of L.O.R.D.S. LLC, said that by “ignoring proximity protections and granting waivers without due process, communities will be oversaturated and [Conditional Adult-Use Retail Dispensary] (CAURD) operators will fail.”  

Currently, 38 other New York CAURD licensees have signed Affirmations of Support for the lawsuit.

End


South Dakota Bill Would Overturn Voter-Passed Medical Cannabis Reforms

a word from our sponsors:

advertisement

advertise here

New legislation from South Dakota state Rep. Travis Ismay (R) is seeking to overturn the state’s voter-approved medical cannabis program, Dakota News Now reports.

It’s not the first time that Ismay, who only recently came into office, has worked to repeal the voter-backed program. As a citizen activist, Ismay collected signatures for a ballot initiative that sought to repeal the law, which itself was established by a voter initiative in 2020.

Melisa Mentele, the executive director for New Approach South Dakota, said in the report that she didn’t understand Ismay’s effort to “completely wipe out” a ballot initiative that had been supported by nearly 300,000 voters.

“His sponsor’s ask is pretty outrageous to wipe out the entire program. It would revert patients back to being convicts. It would shut down a $1,000,000 industry in our state. It would shut down a section of the Department of Health, but it would really have a horrible impact on patients.” — Mentele, via Dakota News Now

Ismay does not currently have any co-sponsors lined up for the bill although he did approach fellow lawmakers to seek their support, the South Dakota War College reports.

South Dakota voters considered and ultimately rejected the legalization of adult-use cannabis last November.

End


Illinois Adds New Medical Cannabis Qualifying Conditions

a word from our sponsors:

advertisement

advertise here

Officials with the Illinois Department of Health last week announced the addition of four new qualifying conditions for the state’s medical cannabis program including , the Chicago Sun-Times reports.

The additions, which take effect immediately, mark the first new conditions added to the state’s medical cannabis program in over five years and bring the total number of conditions approved for the program to 56.

“Medical cannabis has been shown to offer an effective means of relief from a variety of debilitating medical conditions and symptoms. IDPH reviews petitions carefully using expert opinion and the most up to date evidence to make decisions that best serve Illinois residents. IDPH looks forward to working with our medical providers to ensure appropriate access for individuals struggling with these newly approved conditions.” — Vohra, in a statement

Health officials noted that research shows cannabis can help patients manage chronic pain, which is a common symptom for patients with endometriosis, uterine fibroids, and/or ovarian cysts. The health department also noted that cannabis can help patients with female orgasmic disorder, which is a medical condition that makes it difficult or impossible for a woman to have an orgasm.

End


Josh Wurzer: The Realities of Cannabis Testing and Industry Integrity

a word from our sponsors:

advertisement

advertise here

In this episode of the Ganjapreneur Podcast, host TG Branfalt is joined by Josh Wurzer, co-founder of SC Labs, one of the longest-running cannabis testing laboratories in the industry. In this episode, they explore the evolution of cannabis testing, from measuring cannabinoids and terpenes to detecting contaminants like pesticides and mold. Josh shares insights into regulatory challenges, lab fraud, the importance of terpene profiles, and how the industry can better educate consumers to prioritize quality over THC percentages. It’s an enlightening look at the critical role labs play in ensuring cannabis safety and integrity. Listen to the full episode below, or scroll down for the full transcript!


Listen to the episode:


Read the transcript:

Editor’s note: this transcript was automatically generated and may contain errors.

TG Branfalt (00:52):

Hey there, I’m your host, TG Branfalt and this is the Ganjapreneur.com podcast where we try to bring you actionable information and normalized cannabis through the stories of ganjapreneurs, activists and industry stakeholders. Today I am joined by Josh Wurzer, the co-founder of Multi-State operator SC Labs. How are you doing this afternoon, Josh?

Josh Wurzer (01:13):

Excellent. How are you doing?

TG Branfalt (01:15):

Cool, man. Cool. I’m excited to get to what we have to talk to. There’s a lot of stuff in the testing space that I’m hoping you can shine some light on, but before we get to that, tell me about yourself and how you ended up in the cannabis space.

Josh Wurzer (01:30):

Alright, well, so I’ve been in the cannabis space, I guess one way or another since I was in high school. But I always had a love for the plant. I always kind of in one way or another have either added as a part-time job or made a little bit of a living out of cannabis. Went to school though to be a chemist, left school, moved out to California from Wisconsin originally and had a little bit of a grow always on the side that back then it was in the medical marijuana industry. This would be like 2005. But I was working normal jobs, worked in the pharmaceutical industry doing small molecule synthesis for drug discovery. Then worked for Samsung for a long time doing electronic materials, research and development, sort of developing the materials that computer chips and different electronic materials are made out of. And then was one day thinking about maybe what else is out there, just kind of browsing through job postings.

(02:30):

Back then it was Craigslist that people looked for new jobs on in the Bay Area was Bay Area, California, and was reading through a job posting that was for a laboratory director at an analytical law. Looked like a normal job. And then the very end said, must be comfortable working with medical marijuana. Now that was, at that time there was no, certainly no regulated testing industry. Everything was medical, there’s no legal states and there certainly weren’t any cannabis laboratories out there, nothing like there is today. So I just saw that posting. It just piqued my interest just because I kind of always had this interest in cannabis on the side. And so stayed up late that night filling out my resume just so I could get an interview. I wanted to see what they were up to. I had images in my mind like the movie Half Baked, what are these guys doing?

(03:19):

So stayed up late that night, filled up, updated my cv, sent it in, and then went to work the next day and didn’t think too much of it without very much sleep. I think it was up till two in the morning updating my CV and then got a call first thing the next morning, Hey, can you come in for an interview? So went up to Oakland on my lunch break, I was working in San Jose at the time, shout up to Oakland on my lunch break. And what it was is it was the very first testing lab in the country or the world I guess, that focused on medical marijuana. They were just about to open up. It was a couple entrepreneurs and then Steve DeAngelo from Harbor Side

(03:51):

Had gotten together and said, Hey, we need a testing lab. We want to be able to quantify the cannabinoids in the products. We’re selling on the shelves. We think this is a good idea. We’re going to open a testing lab. They kind of set everything up and they were about to open up. And the one science person, they had sort of walked out and they didn’t have a science person, they didn’t have a lab director, so they needed someone with a chemistry background to actually run the lab side of things. And so they’re kind of in a pickle and offered me and gave me the interview. I was into cannabis, I was a scientist, so I think I checked all the boxes and they were in need. So they offered me the job kind of right there. And I didn’t have much time to think about it.

(04:34):

I was kind of thinking about looking for something new in my current job. So I said, I’ll take the job. I never really thought this would be a career. I thought, okay, I’ll do this. Then I’ll start looking for a real job. Of course, I’ll never put this on my resume because I’ll never be able to get a real job if they found out I was working in cannabis. And so now I was the first lab director that was Steep Hill Labs, that was basically the first lab that tested marijuana, medical marijuana, and did that for about a year. And then over the course of that year thought, Hey, this is a great idea, but I think this can be so much more than just testing cannabinoids. And so left there and founded SC Labs. And so we were founded in 2010 and now Steep Hill’s gone in the handful of labs that opened up right after Steep Hill are gone now. So SC Labs is now the oldest operating cannabis lab out there. So we’ve been doing it longer than anyone else that’s still in business.

TG Branfalt (05:33):

Yeah, that’s a crazy story. I’ve interviewed DeAngelo and people from Steep Hill on this podcast several, several years ago. So for people who may not understand, what do cannabis laboratories do and where do they fall on the production chain?

Josh Wurzer (05:54):

Alright, so what we do is we test, first thing is obviously testing the active ingredients in cannabis. So those are the cannabinoids. THC is the one that most people are aware of on C-B-D-T-H-C is the most psychoactive or one of the more psychoactive of the cannabinoids. That’s common in the cannabis plant. The cannabis plant can produce literally dozens of different cannabinoids and most of them are bioactive, interact with your cannabinoid receptors. Some of them are psychoactive, some of them are not like CBD or at least intoxicating. CBD is certainly psychoactive, but it’s not intoxicating. And then also there’s the terpenes which give cannabis it’s flavors and it’s aromas. And actually the cannabinoids themselves are specialized terpenes that only cannabis produces, but cannabis also produces all these other terpenes that other plants produce, like pinine, which is in various pine trees and stuff like that gives its pine smell lemon, which is in citrus fruits that give it that kind of lemon citrusy smell.

(06:54):

And then a bunch of other ones, which is in hops, a bunch of other sort of aromatic compounds. And that’s why cannabis can have such a variety of flavors. And then some of these terpenes are also bioactive on in their own and potentiates sort of the high of cannabis, which is why sort one variety of cannabis will maybe be really sedative. The next will be more uplifting. And so that’s why cannabis is so interesting because it’s got all of these bioactive compounds in it that all interact with your body in slightly different ways. And in cannabis has such a variety of concentrations of these compounds. So one variety of cannabis might have a lot of mercene and a lot of THC and then another variety of cannabis may have very little THC and no.

(07:38):

So it is such a fascinating plan. It’s not like other things like say alcohol, which basically has ethanol one compound that gives you a buzz or whatever. And so basically if I drink tequila, if I drink vodka, some people say, well, I get drunk differently. It’s not very much the case, it’s going to be the same. But with cannabis, that’s not the case. Such a variety of effects it can have. And so that’s what makes it so interesting. So that’s obviously one of the primary things we test for. And then we also test for contaminants a lot of things like pesticides, heavy metals, chemicals that can come through in the processing of cannabis into other products, microbiological contaminants like e coli or salmonella. And so depending on the state we’re working in, they’ll have different tests that are required before a cannabis product can make it to market to ensure that it’s free of some of these contaminants.

(08:37):

And since a lot of forms of cannabis are consumed through inhalation, it’s much more important to be much more stringent with the contaminants you allow in the product because they go directly into the bloodstream, they go through your lungs rather than say maybe something you eat where it goes through your intestines. And there’s a lot of things in your body that can filter those contaminants out. So that’s what we do. And early on, before there was any testing requirements, we sort of did this voluntarily. So we tested for retailers or dispensaries who just wanted to make sure that the products they were putting on their shelves were safe. But now with regulations, this stuff is required to be tested before it ever makes it to the retailer. So now we’re testing either at the manufacturer or the grower part of the supply chain or in California, everything has to flow through a distributor. So we test at the distributor.

TG Branfalt (09:45):

Tell me about, I mean you operate in multiple different states. Is there a typical licensing process for laboratories that is sort of state by state? Or is it something you kind of have to play catch up on or learn about with each state that you decide to enter?

Josh Wurzer (10:02):

Both. So yeah, each state has its own regulations and it has its own sort of regulating body. Sometimes it’s multiple different regulating bodies in a particular state. And then there’s also these international accrediting bodies that accredit laboratories. So for instance, in California we have to hold an international, an ISO 17 0 2 5 accreditation, which is just a standard laboratory accreditation. But then we also have to be licensed by the state and have to meet the state’s requirements for testing laboratory as well. So we have different audits from both of these. We’ll have an audit from our licensing body, and then we’ll also have an audit from our accreditor, either yearly or bi-annually or depending on what it is. And then each state is going to have different requirements of the laboratory, different sort of criteria we have to meet as a laboratory. And then you’re going to have different requirements on each of the tests we perform. And we’re going to be testing for different things in each of the state as well in each state. So state by state, it’s a completely new ball ballgame. Every time we go into a new state, we have to kind of start from square one and build a laboratory just to meet that state’s requirements.

(11:19):

And so yeah, it gets confusing. There’s a lot of overlap, but it still, there’s kind, each state is doing it differently enough where it definitely is, it is tough. And then also on top of that, there’s hemp testing now as well where hemp can cross state lines. So we can test, for instance, we can test hemp from pretty much all 50 states in our California laboratory. But still to meet each of them of those states’ needs, we have to maybe hold different accreditations for that test in that California laboratory to meet the needs of each of the states that we’re going to be testing that hemp for. So yeah, it is confusing. It is also kind of really interesting and is a scientist or someone who likes to solve problems, it can be, it is challenging, but it’s also, that’s where some of the reward is, I guess, in how complex these laboratories have to be, much more so than say a food testing laboratory or an environmental testing laboratory. Cannabis testing is probably one of the more difficult fields to be in if you’re going to be an analytical ems.

TG Branfalt (12:29):

Well, from what I’ve noticed when licensing opens that a lot of times there’s not a lot of licenses filed for or applications for testing labs. Why do you think that is? Is it because of the complications that you just sort of mentioned

Josh Wurzer (12:49):

And we’re an ancillary business and certainly right now in the cannabis industry, people aren’t making money as quickly as maybe they’d hoped five or six years ago. And so when we’re sort of down the food chain on that, so our customers are certainly feeling the financial squeeze. And so there’s a lot of pressure on us to do these really complex tests, meet all of these really complex regulatory requirements and do it much more cheaply than say, a comparable lab in the food or environmental testing arena. And then there’s a lot of companies going out of business and stiffing us with big bills and stuff like that.

TG Branfalt (13:26):

Really.

Josh Wurzer (13:27):

So financially it is been a really tough road to host since we’ve been around so long and we’ve reached a certain scale, we’ve been able to weather the storm. But there’s been a lot of cannabis testing labs that opened up early on and said, oh, well, there’s going to be a ton of money in cannabis. It’s this new industry. Sky’s the limit, got in invested millions and millions of dollars and then went belly up a year or two later. And so it is been tough. And then also there’s all this pressure since now too, a lot of the value of cannabis on the wholesale market is determined to buy our test results by how concentrated the THC is specifically that one thing. And so there’s been a lot of pressure on the laboratories to basically not necessarily return the most accurate results, but return results that are more favorable to our customers, the people requesting the test that to give them a higher THC score that a lot of laboratories just to stay around have played along.

(14:29):

And so there’s been sort of a lot of, for lack of a better word, fraud in the testing industry. It’s different from state to state depending on how tied to wholesale prices that THC concentration is or how strict the regulators are in looking over our shoulders. But that’s certainly been an issue too for labs that aren’t willing to play that game and want to hold their integrity. You’re a being really kind of pressured to perform these tests much cheaper than they should be. And also you’re sort of losing business to laboratories that are cheating, for lack of a better word. I guess

TG Branfalt (15:13):

Mean that’s one of the major issues in the space right now is this inflating THC. And so it’s not in your estimation, I mean, as the person doing the test, it’s not inaccurate testing so much as it is labs trying to meet this high THC testing result demand. Is that correct?

Josh Wurzer (15:31):

Yeah, yeah. And again, it is been so tough financially for labs. I get it. You invest millions and millions of dollars and then someone says, well, I need my THC to be five points higher than it should be. And really our focus to try and fix this has been to try and educate the consumer that the concentration of THC in your say, cannabis flower is not that important if it’s a 30% versus a 20% when you inhale cannabis and then you exhale, you exhale almost all the cannabinoids you just took in. If you inhale and exhale and you don’t hold it in for a long time, there’s a study out there where they measured these concentrations and you basically exhale about 98% of the cannabinoids that you breathe in. So if you wanted to get higher, all you would have to do with that 20% versus that 30% is just hold it in your lungs a little bit longer and give it more time to absorb. And you would basically get the same amount of THC into your system. What really determines the quality of cannabis is the flavor and the aroma.

TG Branfalt (16:44):

It is

Josh Wurzer (16:45):

Kind of this old adage that I’ve been saying for years. You don’t judge a wine on its alcohol content. You judge it on its flavor, its terroir, all that stuff. And hopefully as the cannabis consumer gets more sophisticated, they’ll start looking at things like the terpene concentration and which terpenes are there and what concentration, how much terpenes are left, did they dry it quickly and then throw it in the back of a van with no refrigeration driving it around in a hundred degree weather. And by the time it reaches the retailer, it basically tastes like hay or did they dry and cure it under refrigerated conditions and transport it under refrigerated conditions and make sure it gets to you the consumer with a lot of flavor and aroma? Well, we can measure that too. And that’s much more important than sort of whether it’s a 30% THC or 20% THC. And really early on when we did this testing, most strains we saw were 15 to 20, 25% was a really strong strain.

(17:42):

And a lot of these strains have gone away because they did test higher. But those are some of the more interesting strains. A lot of your purple grapey strains or your Bubba Ks, your Confidentials, these strains that were really popular back in the early two thousands that are pretty much disappeared because they just don’t test really high. It is a shame because that’s not really what gives you quality cannabis. It is that flavor in sort of that unique effect of an interesting terpene profile coupled with an interesting cannabinoid profile. So it is a shame we’ve seen that. But yeah, it is been a major problem with the industry is sort of this hyper focus on that THC concentration. And then also too, there’s also a lot of pressure on the laboratories to maybe look the other way if they see a certain pesticide contaminant or whatever. So laboratories that aren’t maybe as accurate or sensitive on detecting those contaminants also tend to do better with certain customers who would rather just look the other way than address maybe a problem with contamination. So yeah, it’s an issue.

TG Branfalt (18:49):

I think that the problem with the THC and that being the sort of focus also has to go hand in hand with regulations because for example, here in New York, all they require on the packaging is T-H-C-C-B-D content. You can’t smell the products in the store, right? I mean, you’re just going to a screen and you’re picking a brand name or an alleged strain, which I mean, you and I could probably talk about strain names, the problems with those, but that’s not the case in all states. Some states do require that terpene profile to be on the packaging, is that correct?

Josh Wurzer (19:29):

Yes, some do. Some do. And then it is voluntary. So it is something that consumers, I think should look for and sort of demand. In California, it’s not required, but you still see a lot of your high-end brands will include that on the packaging. And I think that’s what a consumer should be looking for. And we’re really encouraging dispensaries also to make it that information more available at the point of purchase rather than just maybe on the packaging after I purchase something, now I can take a look at it. And because like you said, with strains, there’s so many, that whole strain game is kind of fraught with all kinds of different issues. Is it really the strain name that it’s listed at? And then there’s so many new strains all the time. Even me as someone who’s been a cannabis connoisseur for years and years, I walk into a dispensary and I maybe know half of what the strains are, but I know I like pine dominant varieties.

(20:29):

So if I could go into a dispensary and say, Hey, show me all of your pine dominant varieties, I would be happy with most of what I picked and I would be much more apt to try something new that I didn’t know what it was, and I don’t recognize the strain name, but I know it fits into this class. So that’s what we’ve been doing a lot of work on is sort of in our results, is focusing too on these kind of broad categories and developing ways to categorize cannabis based on its chemical signature and sort of put it into categories similar to, again, I’ll use the wine analogy, I don’t need to know every brand of wine, but if I know I like cabs, well then I will go to the cabernet section and then I’ll try a new brand or I’ll try a new kind of cabernet, not necessarily knowing what it is, but knowing that I like Cabernets well, if I can do that with cannabis and I can go beyond just kind of like, is this an indico or sativa?

(21:24):

I can go, I’d like pining dominance. I’m going to go in, I’m going to look through all your pining dominant varieties, and I’m going to try something new. I’m going to try a new brand, I’m going to try a new strain. It is going to make me much, it’s going to help all up the supply chain so that way the grower can be more innovative and put new things on the market and know that they’ll find their consumer. So I think it benefits everyone from the grower to the dispensary to the consumer to start looking at cannabis in these kind of broad flavor and aroma categories rather than just kind of indica sativa or again, what’s the highest THC? Because then otherwise you’re not going to get people being adventurous and exploring and trying these new strains. And like you said, you don’t get to open the package and smell it before you buy it, and you maybe don’t even get to see it.

(22:16):

But even if you see it, you can at a nugget and say, that looks good, but a lot of times the nugget isn’t that appealing, but the flavor is going to be great. And then again, not only all of that, it’s very important how that cannabis was stored, how it was transported, and then how it was stored at the dispensary level to make sure that the aroma sticks through. So maybe we test it as a 3% right after it’s harvested, but it’s possible that it was driven around in a hot van, sat in a dispensary on a shelf and the dispensary doesn’t have good air conditioning. It sat there for six months, and so maybe it had great terpenes when it was harvested, but by the time that consumer opens that package, all those terpenes have boiled off and are gone and it tastes like, hey.

(23:01):

So I think we need to get much more sophisticated, much more advanced in how we treat cannabis, how we treat it from the time it’s harvested to the time it reaches the consumer to make sure that we’re not ruining the product in that process. And I don’t think we do a good job as an industry yet in sort of caring for that cannabis. It is a perishable good. And what makes it desirable are these sort of volatile aromatic compounds that if you don’t treat the cannabis are going to disappear by the time the consumer ever gets a chance to try it.

TG Branfalt (23:32):

Have any dispensary owners or brand owners sort of had this conversation with you and kind of sought out your advice on this? Very,

Josh Wurzer (23:46):

Yeah. We do our best to try and educate ’em early on. Like I said, we almost tested solely for dispensaries because the growers and the people making edibles were still kind of in as quasi legal gray area, so they weren’t as likely to want to come to a laboratory and give us their ID and pay us with a credit card. So we had much more interaction with the actual retailers to help steer it this way. And then for a long time, once legalization happened, all of our customer base shifted up the supply chain. And so we had less interaction with the retail outlets. But with a lot of this lab fraud, now we’re interacting much more at the retail outlet, at the retail level because the retailers are looking to sort of verify the information they’re getting because there’s not as much trust in certain lab testing.

(24:38):

So now we’re testing again, a lot of times for the retailers and the dispensaries to verify the results that they were given when they actually bought the material. And so yes, there’s, in California here, we work with a lot of dispensaries and elsewhere where we’re located and sort of helping them design their shelves around these broad flavor categories. We test for the Emerald Cup and a lot of these other contests, the California State Fair, where now they’re actually judging these cannabis sample strains in their events based on these categories, based on these flavor categories so that they’re not comparing a cabernet to a merlott

(25:20):

So that they’re comparing kind of samples. If I’m a judge and I tend to more of these fruity strains and I get a tline dominant strain, I might downgrade that just because that’s not my favorite. But if I’m comparing that trapline strain against other tline strains, well now they’re all competing on an even playing field. And so we do now have some retailers out here that will sort out their shelves based on these broad flavor categories, but it is been a slow road. And then we also have been really preaching this sort of mantra about how you manage your supply chain and how you make sure that when you harvest this cannabis, it’s as close to that kind of flavor and freshness six months from now when a consumer actually buys it. So how are you harvesting it? How are you drying it? How are you curing it?

(26:16):

How are you storing it until you get it to the retailer? And then how is that retailer storing and how are you transporting it on the way to the retailer? And then how is that retailer carrying for it until it actually goes to a consumer? So more and more I think people are starting to understand these concepts and incorporate them into their supply chain. But yeah, it’s been slow and I think ultimately we will start seeing a lot more sophistication in this regard, and it’s going to benefit the consumer because by the time they get their cannabis, it’s going to be in a lot better shape.

TG Branfalt (26:51):

Well, and I think you’re thinking ahead of the curve here because the cannabis industry is maturing the people. It’s probably when the first one goes online, and probably my late twenties and my tastes have changed as a consumer, and now I would prefer to have the shelves of the dispensary I go to set up in terms of terpene profiles. And so I think it’s very forward thinking and would like to see in more states. I do want to discuss mold and pesticides and sort of those issues because I’ve spoken to growers and brands and distributors who have said that the states often impose a regulations on these things that aren’t necessarily right for the industry. So I wanted to get your take on that, whether or not you think that that’s an accurate statement or if it’s just them with sort of sour grapes.

Josh Wurzer (27:53):

Well, okay. So there’s a lot of different factors to consider when discussing this topic. First of all, the unique way that cannabis is consumed. So again, like I said earlier, when you consume cannabis through inhalation, it goes directly into your lungs. Your lungs don’t have any type of mechanism type filter out contaminants before allowing whatever you breathe in to get into your bloodstream, so you breathe it into your lungs. Your lungs are first in of themselves, very important organs in your body and very sensitive to contaminants. So for instance, if there’s pesticides on that cannabis flower, they can damage your lungs. And even if they don’t, they go directly into your bloodstream. If I eat some pesticides, say in my food, it goes into my digestive system. My digestive system has all types of mechanisms, whether it’s in my stomach, stomach acid or gets into my intestines, these bacteria and stuff to sort of break down those contaminants before they ever enter my system.

(28:53):

But then even still once they get into my system, they go through a first pass in my liver before they even enter my bloodstream and my liver or your liver. Our livers are designed to again, break down contaminants in what we eat before allowing those contaminants to get into your bloodstream. And so you’ve got all of these mechanisms to filter out contamination when you eat something that aren’t there when you inhale it, when determining what is in a safe, safe, or allowable limit of pesticides to be on your food. And we can debate if those tolerances are even appropriate. A lot of those were determined long time ago, and you can make the case that pesticides are poisons, they kill things, and we allow very low level, or we allow lower levels of them in our food. So that way it is cheap and easy to manufacture food and kill pests that would damage crops, but they’re not good for you.

(29:49):

You can’t make that case. But at least we’ve studied them in sort of their effects when consumed orally and have theoretically determined a relatively safe concentration to allow on our foods, but that can’t be sort of transferred to something that we’re inhaling because it’s a completely different route into your body through inhalation. And no pesticides really have been studied for their effects on your body when you consume them through inhalation. So something that’s approved for strawberries, you can’t say, well, then it should be safe on cannabis because it’s apples and oranges. It’s not comparable. And so until these pesticide manufacturers do these studies and determine safe allowable limits for sprain on cannabis through inhalation, and then you also have a thing where these pesticides are one thing when they’re on your cannabis, but also we’re smoking them, so we’re heating them up and breaking them down into other compounds that have completely different toxicity profiles. And so you’d have to study all of those profiles as well because that’s what’s actually reaching your bloodstream.

(31:07):

So certainly what most states have taken is a sort of pretty stringent approach to the allowable levels of pesticides on foods. They are on cannabis, and so they either have very low limits allowable on the cannabis products or they basically say any amount that’s detectable is not allowable. And so certainly though we can grow cannabis organically without the use of these pesticides, and people have figured out how to do that. And pretty quickly before any of these regulations were in the book, and when we were testing this stuff at the consumer level or at the dispensaries, we would see disgustingly high amounts of these pesticides on these products because growers had, no one was looking or they didn’t think anyone was looking, and they would just spray them willy nilly. So you’d see way higher residue limits than it’s even allowable in food end up on these cannabis products, we’d see two or three different pesticides on everything we tested and concentrates.

(32:09):

It was way worse because not only are you concentrating OIDs, but you’re concentrating the pesticides and you’re running from batch to batch to batch in the same equipment. So if you run one pesticide, now you’ve contaminated every batch. You run in that equipment after that with that same pesticide. So we would see seven or eight different pesticides in every concentrate tested at really high limits. And so now that as soon as the regulations came into effect and the government sets limits, people really quickly figured out how to do it without, and so I think cannabis should be an example to the food industry that, hey, this can be done and we can stop putting poison on our food as much as we stopped putting poison into our cannabis products. Now with things like microbiological contaminants, like aspergillus, e coli, salmonella, things like that, these are microbes that when they’re on your cannabis and then you inhale them, can get into your lungs and cause all kinds of havoc, especially if you have a compromised immune system.

(33:08):

Now, you can debate that some of the states might’ve set two stringent rules on some of these microbial contaminants and that, Hey, we’re inhaling microbes all the time with every breath we take and cannabis, we don’t see a ton of these microbial infections from cannabis consumption. And so maybe some of the states have gotten a little bit overzealous and the limits they’ve set for sort of total yeast and mold or things like that on cannabis. But I think by and large, these limits are attainable and you just need your producers to have good hygiene. And really when we see a grower come in and they say, have an aspergillus contamination, which is a fungus that can infect your lungs, it’s real easy. We go onsite at their facility, we go in with swabs, we swab all their services, we find where this aspergillus is growing.

(34:03):

It’s similar to black mold, it’s the thing that we see in houses and stuff like that, and we find where the source of the contamination is. There’s a ton of ways to basically kill those microbes in your facility and bam, the problem solved. So it just takes good coordination between the grower and their laboratory to identify the source of the contaminant and address it rather than just continue to look the other way. And then you’re just going to turn out contaminated product, but it’s not difficult to address. And I think it just comes with the territory in growing cannabis on the legal market these days. And it’s certainly addressable by the producers and the growers, and cannabis is prone to having a lot of pests on it, but there’s organic ways to address these things. And so I tend to think that the good growers aren’t the ones complaining. The people who know what they’re doing can address the problem, and if you’re going to get into this business, it just comes with the territory.

TG Branfalt (35:05):

So how does it end up on dispensary shelves to get recalled? Because I mean, there was a recall in Missouri a year ago, it was like 75,000 products or something like that. And these are massive. I mean, they affect patients in medical states. When we get these recalls, they affect the average consumer who then has to pay kind of higher prices because there’s less supply. So how does it get to that point?

Josh Wurzer (35:31):

Well, so again, work with the reputable laboratory, don’t work with a laboratory that’s giving you the results you want, work with a laboratory that’s giving you accurate results, vet your laboratories because yeah, the producer is going to have to bear the cost of this recall. I would say it’s the cost of testing is really minuscule. In California, a batch of cannabis products is really large. I mean, even flower batches aren’t super large, but even say a 50 pound flower batch, a full panel of testing is going to cost you around three, $400. And then you have a 50 pound flower batch that’s less than 1% of the value of that batch is going to go into testing.

(36:21):

And there are costs that go into producing cannabis without the use of chemical pesticides and stuff like that where it makes it more expensive to produce that batch. But at the end of the day, with wholesale prices on flowers where they are, I would argue that the consumer isn’t paying the cost of a high cost at the retail outlet because of the extra cost of producing the cannabis organically or factoring in these recalls that are starting to happen. I think it’s a lot of other things. There’s sort of inefficiencies with the regulatory bodies. I think regulatory, the states need to ease up on some of their other licensing requirements, ease up on their taxation of cannabis, because that’s the retail price of a pound of cannabis is $500 in California, and we’re still paying $50 an eighth for a top shelf flower. Why is that?

(37:22):

It’s because of all the inefficiencies created by this overregulation in other places in the cannabis supply chain and over taxation, that consumer is still paying such a high price at the retail kind of point where that grower is only getting less than $500 a pound at wholesale and losing their ass, sorry, or losing a ton of money and going out of business. They can’t get more than $500 a pound. But then the consumer is still paying through the nose and is getting driven to the black market. It’s not because of testing, it’s because of all of these other regulatory inefficiencies and over taxation.

TG Branfalt (38:06):

Is there anything though to be said? I mean you and I mean, I don’t know what your age is, but I mean, we spent a lot of years smoking untested cannabis that may or may not have had mold in it. And I mean, I don’t know of really any issues that may have occurred. You mentioned the overregulation. How does a regulatory body balance keeping people safe versus common sense regulation, how would we jive that?

Josh Wurzer (38:41):

I think we’re all figuring it out. I think the regulators need to constantly reassess these sort of panels that they require for testing. So you bring up micro, I think there’s probably ways to walk back some of those micro requirements. I again, would push back that they’re not too hard to meet in most places, but there’s certain, I would say the regulators should be looking for specific species and organisms that are going to cause infection rather than maybe say the overall total yeast and mold. That’s one test that we do in some states we don’t do in California for that reason, we lobbied against that test in California when they were sending their regulations like don’t look for the overall total yeast and mold on that product because most of those yeast and molds that are on a product are natural. Some of them can be beneficial and they’re not going to get anyone sick.

(39:27):

Look for the specific species and organisms that are going to make people sick like aspergillus and specific species of aspergillus. There’s certain species of aspergillus that are totally benign, but then there’s some of them that, yeah, they can get in your lungs and they can cause an infection. And we see them very rarely, maybe less than 1% of the samples we test. And we have the technology now where maybe we didn’t have it 20, 30 years ago when a lot of these food testing regulations were put in place where they just say, well put it on a plate, see how much yeast or mold grows on that plate. And if it’s too much, well then it’s probably contaminated with something and so deny it. Well, no, let people do that because a lot of the sort of organic ways to keep pests off a crop involve using beneficial microbes that keep pests away.

(40:15):

So I think that’s one way you can do it is sort of be more targeted in your approach to these contaminants and which contaminants you allow. We don’t have to use petri dishes anymore. We can go and take a cannabis sample, extract all the DNA in it and look for the specific DNA fingerprint of these specific organisms that are known to make people sick. Same thing with e coli. E coli is on every surface we touch every day, but there’s certain e coli, like e coli oh 1 57 that causes food poisoning and makes you really sick. Well, so rather than look for the overall bacteria on a cannabis product, look for those specific species of bacteria that we know are going to make you sick, and in some states are doing it that way. Some states are taking this kind of more shotgun approach where we’ll just measure the overall yeast and mold contamination, and if it’s too much, we’re going to deny the cannabis from reaching the market.

(41:10):

And I think we’re seeing that issue. Michigan’s a state we work in where they have these total yeast and molds or Colorado, these total yeas and mold requirements, and it’s hard for these growers to make to meet. So then what they do instead is irradiate all the cannabis, which is putting it through a rad source, sort of zaps all the terpenes as well and makes the cannabis just kind of dried up and ruins it when it probably wasn’t contaminated with anything that was going to make you sick in the first place. So states need to constantly kind of, I think go back and reassess these regulations they put in place, make sure that they’re targeted and they really are maximizing the sort of safety to the consumer because putting regulations in place that aren’t making people safer are only increasing costs, are only making it more difficult for the cannabis growers to make a living.

(42:01):

But they also need to constantly reassess and see, do we have the right pesticides on this list? Are people now if we have a list of 60 pesticides that the labs have to test for, well now our growers just going and trying to find pesticides that aren’t on that list and still spraying the crops. And that’s a problem we’re seeing in a lot of states too now is where we just did a piece with the LA Times where they pulled samples off of shelves throughout the state, and we found we tested for not only the pesticides that were supposed to be tested for before those products made to market and found it at a lot of labs were allowing stuff through onto the shelves that were contaminated with the pesticides that they were supposed to be testing for. But then we also tested for pesticides that weren’t on the list required by the state and found that a lot of these growers were using these really gnarly, sort of illegal, banned in the United States, pesticides from China that aren’t on the list that we’re testing for.

(42:57):

And we found these in a lot of these products that were there in just really high levels because they’re like, screw it. We know the list that the labs are looking for, so we’re going to stay one step ahead of them and just put other stuff in there. And so now again, we’re doing a lot of testing at the retail outlets for these pesticides that the state isn’t requiring we test for, but the retailers, we don’t want to give this stuff to our customers or our patients. And so the states need to be more nimble, I think, in developing their regulations. And again, and same thing with taxation and some of these licensing requirements. It’s like if you want to be partners with the industry and you want to make money off of the industry through taxation, well, you can’t choke the industry out at the same time. At some point it gets to be too much. So you have to allow growers to be able to make a living in this business and labs like ours too, that rely on growers to be financially solvent to make our living. And if you just sort of overtax overregulate, then you’re just sort of choking out the industry and driving everyone back to the black market.

TG Branfalt (44:03):

So when you did this study or we partnered with the LA Times and you get these results, I mean, what is your reaction to this? Were you shocked or were you like, yeah, I knew it. I kind of knew it.

Josh Wurzer (44:16):

We’ve known it all along and we’ve been complaining because it’s choking out. It’s choking out the good laps if you’re sort of not doing a good enough job regulating the laboratory business and shoot, I don’t want it is a huge cost to me. It’s a huge burden. It makes me worried that at any time, if I do something wrong, the state’s going to come in and shut me down, but I need it to be there to keep it fit. If you’re into sports, you don’t like it when the referee throws a flag on your team, but if the referees aren’t there, then it’s a free for all. And then the sports ruined. You need referees in the game to keep it fair. And so if the regulators aren’t doing a good enough job looking over our shoulders as laboratories, well then they’re disincentivizing honest, reputable laboratories and you’re incentivizing the cheaters. And so you start to see all the reputable laboratories out of business. The cheaters are the only ones who can make a living, and the consumer is the person that ultimately suffers.

(45:20):

The brands that want to put out contaminated products are the ones that thrive, and the brands with an ethos and who want to make it a good, clean, healthy product for their customers are the ones who go under. So I wasn’t surprised. We’ve been complaining about this for a long time. We’ve been doing everything we can to educate the consumer to look and to vote with their dollar and spend money on quality producers, quality products that are safe, and to try and change the laws as best we can and maybe work with media outlets to shine light on the story. I also come from the cannabis industry before it was legal, and I also am not trying to try to be a narc, for lack of a better term. So we try and work within the system to change things for the better and maybe not try and shine a light. I also understand a lot of these brands are just trying to survive. A lot of these lab operators are just trying to survive. They’ve stuck their life savings into this business. And if everyone else is cheating, either I cheat and I survive or I go under. So you

TG Branfalt (46:26):

Mean it’s the Barry Bonds argument to go back to sports, right, exactly. I got to take steroids so I can be as good as the other guys. I do. With a few minutes that we have left, I do want to ask you about the remediation processes because I’ve heard that products can fail tests and then be put through remediation and then put back into the market, and I’ve never been able to get a clear picture of what that process is. Are you able to elaborate on that at all?

Josh Wurzer (46:59):

And it’s different depending on the contamination. So for a microbiological contaminant, you have to kill that microbe, and then it’s not going to make people sick for the most part, except for some microbes produce toxins, like certain aspergillus strains produce what’s called mycotoxins, which are super toxic compounds. So it’s hard to remediate those. But for instance, Abbi in a product, well, I can just kill that e coline and then I can put the product back up in the market and it shouldn’t make people sick. So you can either irradiate it and sterilize it, you can do some sort of extraction process on it that uses some sort of chemical solvent that, again, will kill the microbes. So there’s different things you can do to either sort of kill the microbes on the product and then put the product in market or turn the product into something else, will then sterilize it.

(47:48):

But now you have to take this flower and turn it into a concentrate if maybe you didn’t want to do that. If it’s a pesticide, there’s ways to sort of filter that pesticide out, say from a concentrate, but those for the most part are not financially viable solutions. So what people usually do is dilution is the solution to pollution is what we say in chemistry. And so what they’ll do is they’ll extract that product and then they’ll put it into an edible where now instead of consuming a hundred milligrams of the cannabinoid in a serving, the consumers only consuming 10 or 15 milligrams and they’re eating it rather than inhaling it. So a lot of times with pesticide contaminants, you just see people basically turn it into edibles.

TG Branfalt (48:34):

That’s super interesting, man. This has been a super insightful conversation. Where can’t people find out more about you and SC Labs?

Josh Wurzer (48:44):

Alright, well, you can go to our website, it’s SC labs.com. We have a lot of educational material in there too. So if you’re just a general consumer and you want to learn more about the science of cannabis and what we’ve been doing over the years, it’s a great place to start. We’re on all the socials, either myself personally or as SE labs. We put a lot up on Instagram and Facebook and LinkedIn. I am trying to be more active in the socials personally, and so I’m trying to put more content up in LinkedIn. And we have a blog on our website. I just tell people to look us up there.

TG Branfalt (49:21):

It’s Josh we, he’s the co-founder of Multi-state operator SC Labs. Man, it’s really been a pleasure and I hope that we get to do this again in the future and that the landscape is a little bit different. Wouldn’t that be nice?

Josh Wurzer (49:33):

Yeah, yeah. Well, we’re learning, we’re still a young industry and I think we’re just trying to get better, trying to figure it out, and it will be. We’re getting there.

TG Branfalt (49:41):

Thank you so much, man. I really appreciate it.

Josh Wurzer (49:44):

Likewise.

 

End


DoorDash Now Offering Hemp-Derived THC and CBD Product Deliveries

a word from our sponsors:

advertisement

advertise here

The online food and grocery ordering tech company DoorDash announced on Thursday it has expanded its services to include on-demand delivery of hemp-derived THC and CBD products. DoorDash users in areas where the hemp products are available should now see a CBD/THC tab in the company’s app.

The company utilizes ID verification technology and protocols developed for its alcohol delivery services to ensure customers are of legal age.

Jacob Morello, the director and general manager of Alcohol and Emerging Categories at DoorDash, said the expansion aims to satisfy the growing demand for hemp-derived cannabinoid products across the country.

“With the growing demand for hemp-derived THC and CBD products, we’re excited to expand access to a wide selection of products consumers crave. As preferences evolve, DoorDash can now help eligible customers find new products to safely enjoy while they unwind and recharge in the new year.” — Morello, in a statement

The most popular hemp products ordered during the pilot phase of DoorDash’s new business model included gummies, beverages, mints, chocolates, and honey sticks, the company said.

End


Court Says Alerts by Drug Dogs Trained on Cannabis No Longer Justify Police Searches

a word from our sponsors:

advertisement

advertise here

A Florida appeals court ruled this week that because drug detection K9s utilized by police are incapable of distinguishing between illegal cannabis products and legal products like medical marijuana or hemp products, a drug-sniffing dog’s alert to the presence of drugs is not enough to justify a vehicle search, according to the News Service of Florida.

The case covered a September 2020 traffic stop during which a Groveland police officer stopped a Lyft driver for speeding. The officer called in a K9 drug detection dog named Polo, which signaled the presence of drugs in the car. Police searched the vehicle and found drugs including cannabis, cocaine, ecstasy, and methamphetamine, the report said, leading to the arrest of the Lyft driver’s passenger, Stephon Ford.

Ford had argued — unsuccessfully, at first — that the alert of a drug dog trained for cannabis should be inadmissible evidence as it’s no longer clear if they are alerting for an illegal substance. However, the 5th District Court of Appeals agreed with Ford and overturned the previous ruling by a circuit court judge on Tuesday.

“At the time when Polo alerted to a target substance in the Lyft vehicle, the police officers had no way of knowing whether Polo had detected an illegal substance (marijuana, cocaine, heroin, or methamphetamines) or a legal substance, namely the THC in hemp or medical marijuana that was properly prescribed and in the possession of a bona fide medical marijuana card holder. … Whether the substance Polo smelled was legal or illegal was not readily apparent, and thus his alert, alone, could not provide the probable cause needed to justify a warrantless search.” — Chief Judge James Edwards, in the court’s main opinion

In a concurring opinion, Judge Jordan Pratt of the court wrote that under this week’s ruling, “dogs trained to alert on cannabis can no longer provide the sole basis for a stop or search.”

“An alert by a dog trained not to alert to cannabis — or to alert to cannabis differently than it alerts to other drugs — can still on its own supply probable cause,” Pratt wrote.

End


Federal Court Reaffirms Government Can’t Strip Citizens of Gun Rights for Cannabis Use

a word from our sponsors:

advertisement

advertise here

In a decision published Monday, the U.S. 5th Circuit Court of Appeals reaffirmed that the federal government violated the Second Amendment in its prosecution of Patrick Darnell Daniels Jr. for illegally possessing a firearm because he also consumed cannabis.  

Judges from the Southern District of Mississippi Court unanimously ruled that the government’s prosecution of Daniels Jr. for violating 18 USC 922(g) (3) – which makes it a felony for an “unlawful user” of controlled substances to possess a firearm – “is inconsistent” with the U.S.’s “‘history and tradition’ of gun regulation” and fails the test the Supreme Court established in New York State Rifle & Pistol Association v. Bruen (2022).

“The government has not pointed to sufficiently analogous historical laws to establish why Daniels himself should be considered presumptively dangerous. And, as explained, even had the government supplied sufficient historical briefing to support a theory of dangerousness, the jury instruction employed in Daniels’s trial was too open-ended to support his conviction because it left open the possibility that Daniels had not even unlawfully used a controlled substance in several weeks.” — United States of America v. Patrick Darnell Daniels, Jr. decision, 1/6/25

Daniels was arrested in April 2022 during a routine traffic stop in Hancock County, Mississippi after he was found with guns and a few joint roaches. He was convicted of illegal gun possession and sentenced to nearly four years in prison along with three years of supervised release. The conviction also meant that Daniels permanently lost his right to possess firearms. The 5th Circuit had vacated that conviction, citing the Bruen test, in August 2023, but the U.S. Supreme Court vacated that decision in light of the June 2024 decision in U.S. v. Rahimi, which upheld a law banning firearms possession by anyone subject to a restraining order for domestic violence, forcing the 5th Circuit to reconsider its ruling. 

In February 2023, a federal judge in Oklahoma ruled the federal statute barring firearms ownership from cannabis consumers is unconstitutional and in April a federal judge in the U.S. District Court for the Western District of Texas came to the same conclusion. Last year the 5th Circuit ruled that prosecutors cannot file gun possession charges against a Texas woman who admitted to being a cannabis user, that case (U.S. v. Connelly) was cited in the Daniels decision.

End


Nearly Half of Adult-Use Cannabis Licenses Issued in New Jersey Awarded to Minority-Owned Businesses

a word from our sponsors:

advertisement

advertise here

Nearly half – 47% – of all adult-use cannabis licensees awarded annually in New Jersey are majority minority-owned businesses, with 44% issued to majority women-owned or majority disabled veteran-owned, according to state Cannabis Regulatory Commission (CRC) data.

The agency notes that while just 10% of businesses in the state are Black-owned, 17% of cannabis licenses went to Black-owned entities and 13% of cannabis licenses were awarded to Asian-owned businesses despite them comprising only 10% of state businesses. 

As of November 2025, there were 338 cannabis business licenses and permits currently in operation: 251 for adult-use (including expanded Alternative Treatment Centers) and 87 for medical purposes, according to the CRC. During the first three quarters of 2024, the adult-use market generated $722,921,233 while the medical cannabis market generated $66,927,020 during the same period. Overall, the state’s cannabis industry generated $43,290,543 in tax revenue and collected $2,248,270 in social equity excise fees.

Flower was the top-selling product in New Jersey last year, accounting for just over 41% of the market. Vape cartridges ranked second, making up 29%, while edibles represented 14% of sales. The remaining 17% of the market consisted of pre-rolls, concentrates, shake and trim, capsules, pills, lotions, creams, and tinctures, according to the CRC.

According to the CRC, municipalities in the state are still slow to allow industry operations with just 206 of the state’s 564 municipalities (36%) allowing at least one class of cannabis business.

End


Minnesota’s Top Cannabis Official Resigns

a word from our sponsors:

advertisement

advertise here

Minnesota Office of Cannabis Management (OCM) Director Charlene Briner resigned on Monday. Eric Taubel, OCM general counsel, will serve as interim director. In a statement, Gov. Tim Walz (D) said Briner “has gotten Minnesota’s emerging cannabis industry off the ground in a safe and responsible way” and Taubel “will ensure continued growth and success as we work to make Minnesota competitive in this new industry.”    

“It’s no easy task to build a regulatory framework around an entirely new industry from scratch, but under Charlene’s leadership, Minnesota laid the foundation for a successful marketplace for years to come. I am excited to welcome Eric Taubel as the new interim director. Eric is a proven, effective leader who brings legal expertise and a deep understating of state government and regulatory affairs.” — Walz in a press release 

During her time as interim director, Briner oversaw the implementation of Minnesota’s cannabis legislation, including: establishing a new state office that now employs more than 100 staff; conducting an extensive rulemaking process to define regulations for the commercial cannabis industry, which will be finalized by the end of the first quarter of the year; developing compliance and enforcement programs for the hemp-derived cannabinoid market; and facilitating submission and review of more than 1,800 business license applications. 

Taubel will officially take over on January 17. 

Briner’s resignation comes less than a month after OCM abandoned its planned social equity licensing plan amid lawsuits, opting instead for general licensing sometime this year.  

End